Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD-370 Phase II Route of Administration Study in Infants
jRCT2080223918Phase 2Completed
- Sponsor
- KM Biologics
- Start
- May 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of Quentiv in Haemophilus influenzae type b disease (Hib), pertussis, diphtheria and 2 more (2 arms), sponsored by KM Biologics. Primary endpoints: Immunogenicity comparison between intramuscular and subcutaneous KD-370 and Safety and injection-site reactogenicity. Started May 2018; status: completed.
02
Drugs
Quentiv
03
Conditions
Haemophilus influenzae type b disease (Hib)pertussisdiphtheriaTetanuspoliomyelitis
Beyond the preview
Go deeper on jRCT2080223918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223918.